Patents by Inventor Andrew T. Maioli

Andrew T. Maioli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Patent number: 7872025
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: January 18, 2011
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Patent number: 7557128
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: July 7, 2009
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Publication number: 20090149502
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
    Type: Application
    Filed: February 12, 2009
    Publication date: June 11, 2009
    Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Publication number: 20080287498
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
    Type: Application
    Filed: April 30, 2007
    Publication date: November 20, 2008
    Inventors: A.K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Optically active isomers of ketotifen and therapeutically active metabolites thereof
    Patent number: 7226934
    Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen.
    Type: Grant
    Filed: September 12, 2000
    Date of Patent: June 5, 2007
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
  • Smooth muscle spasmolytic agents
    Patent number: 7141696
    Abstract: The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, and other smooth muscle contractility conditions. More particularly, the present invention relates to certain metabolically stabilized secondary amines having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: November 28, 2006
    Assignee: Bridge Pharma, Inc.
    Inventors: A. K. Gunnar Aberg, Jan L. Chen, Andrew T. Maioli, George E. Wright
  • Smooth muscle spasmolytic agents
    Publication number: 20040248987
    Abstract: The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, and other smooth muscle contractility conditions. More particularly, the present invention relates to certain metabolically stabilized secondary amines having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects.
    Type: Application
    Filed: May 21, 2004
    Publication date: December 9, 2004
    Inventors: A.K. Gunnar Aberg, Jan L. Chen, Andrew T. Maioli, George E. Wright